Navigation Links
Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2012 at 2:00 p.m. PT / 5:00 p.m. ET. Greg I. Frost, Ph.D., president and chief executive officer of Halozyme Therapeutics, will provide a corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. The Company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition to partnerships that use Halozyme's ENHANZE™ Technology, the Company has a number of product candidates in its pipeline that target multiple areas of significant unmet medical need. For more information, visit www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

 


'/>"/>
SOURCE Halozyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
2. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
3. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
4. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
5. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
8. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
9. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
10. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
11. Halozyme Receives $5.5 Million Payment From Baxter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:9/1/2014)... NewYork (PRWEB) September 01, 2014 ... Biotech and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading life ... understand and analysis of how and why companies ... of a prospective partner’s negotiated deals terms provides ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... ... the availability of two new atomic force microscope (AFM) probes types with carbon nanotube ... CNT probes offer quantum improvements for AFM imaging, substantially improving results, reducing overall cost ... ...
... FRANCISCO, Calif., June 16 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment of ... Executive Officer of Sunesis, will be presenting at the Jefferies ... New York on June 17, 2009. , , The ...
... 16 Three Rivers Pharmaceuticals announced today positive results ... Efficacy of Combined Therapy (DIRECT) clinical trial authored by ... , and colleagues at 44 centers in the United ... (SVR), was achieved demonstrating that INFERGEN provides a second ...
Cached Biology Technology:Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 2Carbon Design Innovations, Inc. Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy, CNT-Probes Deliver New Level of AFM Imaging Performance 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 2Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 3Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures 4
(Date:9/2/2014)... to prevent Type 2 diabetes, don,t get your hopes up. ... The FASEB Journal , suggests that you don,t ... study compared genetically identical twins-one heavier and one leaner-and found ... those related to Type 2 diabetes, were found in both ... the onset of this type of diabetes is largely influenced ...
(Date:9/2/2014)... your integrity? Tell the truth; everyone has a tipping point. ... we,ll lie if the benefit is great enough. Now, scientists ... make that decision. , The result was published online ... "We prefer to be honest, even if lying is beneficial," ... associate at the Virginia Tech Carilion Research Institute , ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2
... Calif. UC Riverside,s Alexander Raikhel , a professor ... National Academy of Sciences (NAS) for his excellence in ... is one of the highest honors given to a scientist ... inducted into the academy next April during its 147th annual ...
... the 61st Annual Meeting of the Rocky Mountain Section ... May 2009 in Orem, Utah. Utah Valley University ... building on the UVU campus. Brigham Young University is ... industry scientists, and graduate and undergraduate students, will highlight ...
... million in U.S. dollars have been awarded to ... studies related to asthma and other immune system ... extramural grants were awarded by the Biomedical Research ... and Research), the government agency driving Singapore,s transformation ...
Cached Biology News:UC Riverside professor receives top scientific honor 2UC Riverside professor receives top scientific honor 3Geoscientists meet to discuss Rocky Mountain geology 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 3Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 4
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Biology Products: